Researchers who plan to keep Retatrutide in storage for longer periods should check vials periodically to confirm that seals remain intact and no condensation or visible changes have occurred
Measurements should be taken at consistent times, after 5 minutes of rest, using a validated upper-arm cuff device (not wrist or finger devices)
Indications: Obesity (BMI 30 kg/m) Overweight (BMI 27 kg/m) with weight-related comorbidities Should be used with dietary and physical activity interventions Contraindications: Hypersensitivity to semaglutide or excipients Pregnancy or breastfeeding Personal/family history of medullary thyroid carcinoma Diagnosis of MEN 2 Side Effects: Very common (10%) : Nausea, vomiting, diarrhea, constipation Common (110%) : Headache, dizziness, fatigue, reflux Less common/rare : Gallstones, pancreatitis, renal impairment Reports of suicidal ideation in post-market surveillance Each pen delivers 2.4 mg of semaglutide in 0.5 mL of clear, colorless solution
March 8, 2024 The FDA approved Wegovy to lower the chances of cardiovascular death, heart attack and stroke in people with cardiovascular disease who are obese or overweight
The Patent Portfolio: A Layered Defense Novo Nordisks strategy spans compound, formulation, and method-of-use patents, listed in the FDAs Orange Book
